Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Mark A. Marzinke"'
Autor:
Kelong Han, Mark Baker, Mark Lovern, Prokash Paul, Yuan Xiong, Parul Patel, Katy P. Moore, Ciara S. Seal, Amy G. Cutrell, Ronald D. D'Amico, Paul D. Benn, Raphael J. Landovitz, Mark A. Marzinke, William R. Spreen, Susan L. Ford
Publikováno v:
British journal of clinical pharmacology, vol 88, iss 10
AimTo characterize cabotegravir population pharmacokinetics using data from phase 1, 2 and 3 studies and evaluate the association of intrinsic and extrinsic factors with pharmacokinetic variability.MethodsAnalyses were implemented in NONMEM and R. Co
Autor:
Asama Tanaudommongkon, Ayyappa Chaturvedula, Craig W. Hendrix, Edward J. Fuchs, Eugenie Shieh, Rahul P. Bakshi, Mark A. Marzinke
Publikováno v:
British journal of clinical pharmacology. 88(8)
Transgender women (TGW) have been underrepresented in trials and use gender-affirming hormonal therapies (GAHT) that may alter renal function by significantly increasing creatinine clearance. Population pharmacokinetic (popPK) models and simulations
Autor:
Kelong Han, Kalpana Bakshi, William Spreen, Yu Lou, David A. Margolis, Craig W. Hendrix, Sharon A. Riddler, Edward J. Fuchs, Ronald D'Amico, Jafar Sadik Shaik, Susan L. Ford, Parul Patel, Stacey Edick, Ethel D. Weld, Mark A. Marzinke
Publikováno v:
British journal of clinical pharmacology. 88(4)
Aims Cabotegravir is an integrase strand transfer inhibitor in clinical development as long-acting (LA) injectable HIV preexposure prophylaxis. Methods This phase I study assessed pharmacokinetics of cabotegravir in plasma and anatomical sites associ